Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients (AVD-Rev)

University of Cologne

Status and phase: Completed; Phase 1

Conditions: Hodgkin Lymphoma

Treatments: Drug: Vinblastine; Drug: Lenalidomide; Drug: Doxorubicine; Drug: DTIC

Study type: Interventional

Funder types: Other

Identifiers

NCT01056679

AVD-Rev

Details and patient eligibility

About

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Enrollment: 30 estimated patients

Sex: All

Ages: 60 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hodgkin Lymphoma, intermediate or advanced stage
• Age >60 and <75 years
• ECOG 2 or better
• No major organ dysfunction
• Ability to take aspirin or LMW Heparin

Exclusion criteria

• HL as composite lymphoma
• Prior use of lenalidomide
• Prior use of chemo- or radiotherapy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

AVD-Rev

Experimental group

Description:

Patients with intermediate stage HL receive 4 cycles of AVD-Rev followed by 30 Gy IF-RT Patientes with advanced stage HL receive 6 to 8 cycles of AVD-Rev followed by 30 GY IF-RT depending on the FDG-PET results

Treatment:

Drug: DTIC

Drug: Doxorubicine

Drug: Vinblastine

Drug: Lenalidomide